Alan Tan

Thanks @CureMelanoma for the opportunity to discuss ctDNA in #melanoma, also thanks to my son Auguste for the #cameo appearance!

@tompowles1 @DrKarineTawagi If trying to test as single arm, why not test several approaches after CCR after 4 cycles EVP. i.e. TAR-200/Pembro, adstilidrin, chemoRT, IO alone, observation. @MattGalsky HCRN trial will be important to observe. Also VOLGA.

@tompowles1 @DrKarineTawagi Others have already expressed the same concerns I have. 9 cycles is enough to develop irreversible PN, and some other severe AE’s. We need an adaptive approach utilizing ctDNA. utDNA might not be ready yet, but we’re getting closer. We need to do better for our patients.

A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert

PREDICT-DNA study utilizing NeXT Personal® (n=227) shows ctDNA status post-neoadjuvant therapy predicts breast cancer recurrence better than pathologic complete response (pCR). ↳ 100x higher relapse risk if ctDNA+ post-surgery (up to 12 months) ↳ 55% of all ctDNA detections <100 ppm ↳ ctDNA-negative = excellent outcomes regardless of pCR status This is what ultrasensitivity looks like. Discover more: bit.ly/4lFGgjx bit.ly/4lABdAU #PrecisionOncology #BreastCancer #ctDNA #MRD #CancerResearch #CancerDiagnostics #TNBC @benhopark, @hthrparsons, @RitaNandaMD, @AngieDemichele, @guptalabunc, @FilipaLynce, @DrShelleyHwang, @DrWalidElAyass, @awolff, @FNavarroBioInfo

Urine tumor DNA as a biomarker for high-risk #BladderCancer recurrence and guidance. @UrogerliMD @MoffittNews joins @UroCancerMD @VUMCurology to discuss minimal residual disease detection using urinary tumor DNA in #NMIBC. #WatchNow on UroToday > bit.ly/4jNnMwG

⚡️AI-assisted cystoscopy is getting closer to real-world use. In RAISE-01, a vendor-independent tool (CystoAID) trained on routine videos reached external-validation sensitivity 1.00 with ~88% precision, designed to reduce missed lesions during standard white-light cystoscopy. Prospective impact studies next. #BladderCancer #NMIBC #AI @OncoAlert pubmed.ncbi.nlm.nih.gov/41833082/

First-in-human Nectin4-targeted fluorescence imaging for TURBT #EAU26 @urotoday • Diagnostic accuracy: 96% vs 85.6% with WLC • Tumor margin detection: 91.1% vs 72.2% • Ex vivo biopsy accuracy: 96.3% • Preclinical models doubled complete resection rates Probe demonstrated a favorable safety profile

A fantastic summary of what’s next in bladder cancer # EAU26 by @scocmem 1) VEGF/PD1 bispecifics and RNA vaccines are promising IOs 2) Novel ADCs like IZABREN (HER1&3) and SAC-TMT in RIII trials 3) New FGFR3 specific targeted therapies as personalized triplets (Vepugratinib/EVP) = FORAGER-2 4) TAR-200 vs BCG in MIBC will have a big impact is postive in R3 @urotoday @EUplatinum @Annals_Oncology @OncoAlert @UroDocAsh

Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert

Circulating and urine tumor DNA dynamics predict minimal residual disease and recurrence risk in locally advanced #UTUC: CURATE-UTUC – A multicenter prospective longitudinal cohort study. Presentation by Jiwei Huang. #EAU26 written coverage by @zklaassen_md > bit.ly/473DONU @Uroweb

@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26 ➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26) ➡️ 89% CR at 6 months in IR NMIBC ablative cohort Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS

⚡️ Variant histology in MIBC isn’t a footnote—it can drive staging, relapse risk, and response to systemic therapy. This review highlights a persistent problem: subtype misclassification (and why expert/central pathology matters), plus the push for trials that include variant subtypes rather than excluding them. #BladderCancer #MIBC #UroOnc dailynews.ascopubs.org/do/advancing-p…

5/Further analyses from CheckMate 214 show that patients who discontinued nivo + ipi due to immune-mediated adverse events (IMAEs) had a 40% OS rate at 108 months, compared with 31% in the overall ITT population. Within the nivo + ipi arm, 108-month OS was 40% in those who discontinued for IMAEs vs 29% in those who did not (HR 0.47, 95% CI 0.36-0.62).

2/Nivolumab + ipilimumab maintained a significant OS benefit vs sunitinib (HR 0.71, 95% CI 0.62-0.82), with longer mOS (52.7 vs 37.8 mo) and higher 108-month OS rate (31% vs 20%). PFS rate at 96 m (23% vs 9%) and DOR (76 vs 25 mo) also favored the combination.

Excited to review our paper on KIM-1 and ctDNA in oligomet RCC and the K-COMPASS prognostic model published this wk in @EuropeanUrology. Great collaboration between @UTMDAnderson and @DanaFarber. Specifically @VincentWenxinXu and @DrChoueiri Full paper: authors.elsevier.com/a/1mhMr14kpm4V…

@AndreaNecchi presents the final results of SUNRISE-2 with tar200+IO vs chemoRT showing no benefit of TAR200+IO compared chemoRT. Important negative study! @ASCO #GU26

BREAKING at #GU26: The Phase 3 LITESPARK-022 study meets its primary endpoint. Adjuvant pembrolizumab + belzutifan significantly improved Disease-Free Survival (DFS) vs pembro alone for clear cell RCC at risk of recurrence: 🔹 HR: 0.72 (95% CI, 0.59–0.87) 🔹 P = 0.0003 🔹 OS data still immature (HR 0.78) Safety: Anemia was the most common AE in the combo arm (84%). #KidneyCancer #RCC #OncTwitter

Belzutifan + lenvatinib significantly improved Progression-Free Survival (PFS) vs. cabozantinib for patients with advanced ccRCC post-immunotherapy: • Median PFS: 14.8 mo vs. 10.7 mo (HR 0.70; p=0.00007) • Risk Reduction: 30% reduction in disease progression or death, duration of response 23 m • ORR: Statistically significant improvement over cabozantinib 🧬 #KidneyCancer #OncTwitter #LITESPARK011

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

📍 At #GU26 in SF? Stop by our poster sessions! TODAY, 11:30 AM-12:45 PM | West Hall, Level 1 Poster L20: Real-world NeXT Personal® results in urothelial carcinoma w/ @alantanmd & @mm_zerey (@VUMCDiscoveries). TOMORROW, 7:00-8:10 AM | West Hall, Level 1: Recurrence risk in high-risk localized RCC w/ Paulo Siqueira Amaral & Dr. Tan. See you there! 🔬 Connect with us at ASCO GU: bit.ly/4udAtG2. #PrecisionOncology #BladderCancer #KidneyCancer

“A picture is worth a thousand words.” #GU26 @ASCO Prostate rapid oral abstracts presented by Dr DeBono of a first in class masked T cell engager (VIR-5500) in mHRPC.